TY - JOUR
T1 - Three-month treatment with triptorelin, letrozole and ulipristal acetate before hysteroscopic resection of uterine myomas
T2 - prospective comparative pilot study
AU - Bizzarri, Nicolò
AU - Ghirardi, Valentina
AU - Remorgida, Valentino
AU - Venturini, Pier Luigi
AU - Ferrero, Simone
PY - 2015/9/1
Y1 - 2015/9/1
N2 - Abstract Objective To compare the usefulness of preoperative treatment with triptorelin, letrozole or ulipristal acetate or no treatment before hysteroscopic removal of uterine submucosal myomas. Study design Single center prospective non-randomized comparative pilot study. The study included consecutive premenopausal patients undergoing hysteroscopic resection of myomas graded as type 0, type 1 or type 2 according to the FIGO classification with diameter between 20 and 35 mm. Exclusion criteria were: associated polyps, associated non-hysteroscopic surgical procedures, >2 myomas requiring hysteroscopic resection. This study enrolled patients who underwent either direct surgery (group S; n = 23) or 3-month preoperative treatment with triptorelin (3.75 mg every 28 days; group T; n = 20), letrozole (2.5 mg/day; group L; n = 11) or ulipristal acetate (5 mg/day; group U; n = 7). Patients underwent hysteroscopic resection of the myomas. Results All medical treatments caused a significant decrease in the volume of myomas (group T, p
AB - Abstract Objective To compare the usefulness of preoperative treatment with triptorelin, letrozole or ulipristal acetate or no treatment before hysteroscopic removal of uterine submucosal myomas. Study design Single center prospective non-randomized comparative pilot study. The study included consecutive premenopausal patients undergoing hysteroscopic resection of myomas graded as type 0, type 1 or type 2 according to the FIGO classification with diameter between 20 and 35 mm. Exclusion criteria were: associated polyps, associated non-hysteroscopic surgical procedures, >2 myomas requiring hysteroscopic resection. This study enrolled patients who underwent either direct surgery (group S; n = 23) or 3-month preoperative treatment with triptorelin (3.75 mg every 28 days; group T; n = 20), letrozole (2.5 mg/day; group L; n = 11) or ulipristal acetate (5 mg/day; group U; n = 7). Patients underwent hysteroscopic resection of the myomas. Results All medical treatments caused a significant decrease in the volume of myomas (group T, p
KW - GnRH analog therapy
KW - Hysteroscopy
KW - Letrozole
KW - Myomectomy
KW - Submucous fibroid
KW - Triptorelin
UR - http://www.scopus.com/inward/record.url?scp=84938489751&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84938489751&partnerID=8YFLogxK
U2 - 10.1016/j.ejogrb.2015.06.018
DO - 10.1016/j.ejogrb.2015.06.018
M3 - Article
C2 - 26142912
AN - SCOPUS:84938489751
VL - 192
SP - 22
EP - 26
JO - European Journal of Obstetrics, Gynecology and Reproductive Biology
JF - European Journal of Obstetrics, Gynecology and Reproductive Biology
SN - 0028-2243
M1 - 9027
ER -